174 related articles for article (PubMed ID: 17471586)
1. Human osteocalcin: a strong promoter for nitric oxide synthase gene therapy, with specificity for hormone refractory prostate cancer.
McCarthy HO; Coulter JA; Worthington J; Robson T; Hirst DG
J Gene Med; 2007 Jun; 9(6):511-20. PubMed ID: 17471586
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of a synthetic CArG promoter for nitric oxide synthase gene therapy of cancer.
Worthington J; Robson T; Scott S; Hirst D
Gene Ther; 2005 Oct; 12(19):1417-23. PubMed ID: 15902277
[TBL] [Abstract][Full Text] [Related]
3. Prostate-specific antigen promoter/enhancer driven gene therapy for prostate cancer: construction and testing of a tissue-specific adenovirus vector.
Latham JP; Searle PF; Mautner V; James ND
Cancer Res; 2000 Jan; 60(2):334-41. PubMed ID: 10667585
[TBL] [Abstract][Full Text] [Related]
4. The radiation-inducible pE9 promoter driving inducible nitric oxide synthase radiosensitizes hypoxic tumour cells to radiation.
Coulter JA; McCarthy HO; Worthington J; Robson T; Scott S; Hirst DG
Gene Ther; 2008 Apr; 15(7):495-503. PubMed ID: 18256696
[TBL] [Abstract][Full Text] [Related]
5. Transcriptional regulation of inducible nitric oxide synthase gene therapy: targeting early stage and advanced prostate cancer.
Coulter JA; Page NL; Worthington J; Robson T; Hirst DG; McCarthy HO
J Gene Med; 2010 Sep; 12(9):755-65. PubMed ID: 20821746
[TBL] [Abstract][Full Text] [Related]
6. Gene therapy for prostate cancer by targeting poly(ADP-ribose) polymerase.
Trofimova I; Dimtchev A; Jung M; Rosenthal D; Smulson M; Dritschilo A; Soldatenkov V
Cancer Res; 2002 Dec; 62(23):6879-83. PubMed ID: 12460902
[TBL] [Abstract][Full Text] [Related]
7. p21((WAF1))-mediated transcriptional targeting of inducible nitric oxide synthase gene therapy sensitizes tumours to fractionated radiotherapy.
McCarthy HO; Worthington J; Barrett E; Cosimo E; Boyd M; Mairs RJ; Ward C; McKeown SR; Hirst DG; Robson T
Gene Ther; 2007 Feb; 14(3):246-55. PubMed ID: 17006546
[TBL] [Abstract][Full Text] [Related]
8. Regulation of TGF-beta1 gene transcription in human prostate cancer cells by nitric oxide.
Wang D; Lu S; Dong Z
Prostate; 2007 Dec; 67(16):1825-33. PubMed ID: 17941092
[TBL] [Abstract][Full Text] [Related]
9. Probasin promoter (ARR(2)PB)-driven, prostate-specific expression of the human sodium iodide symporter (h-NIS) for targeted radioiodine therapy of prostate cancer.
Kakinuma H; Bergert ER; Spitzweg C; Cheville JC; Lieber MM; Morris JC
Cancer Res; 2003 Nov; 63(22):7840-4. PubMed ID: 14633711
[TBL] [Abstract][Full Text] [Related]
10. [Transfection of iNOS suppresses the growth of androgen-independent prostate cancer DU145 cells].
Chen YF; Jiang XZ; He LY; Tang YX; Long Z
Zhonghua Nan Ke Xue; 2012 Aug; 18(8):697-702. PubMed ID: 22934514
[TBL] [Abstract][Full Text] [Related]
11. Prostate-tumor targeting of gene expression by lentiviral vectors containing elements of the probasin promoter.
Yu D; Jia WW; Gleave ME; Nelson CC; Rennie PS
Prostate; 2004 Jun; 59(4):370-82. PubMed ID: 15065085
[TBL] [Abstract][Full Text] [Related]
12. Prostate-specific antigen promoter driven gene therapy targeting DNA polymerase-alpha and topoisomerase II alpha in prostate cancer.
Lee CH; Liu M; Sie KL; Lee MS
Anticancer Res; 1996; 16(4A):1805-11. PubMed ID: 8712704
[TBL] [Abstract][Full Text] [Related]
13. Expression of Drosophila Ca2+ permeable transient receptor potential-like channel protein in a prostate cancer cell line decreases cell survival.
Zhang L; Brereton HM; Hahn M; Froscio M; Tilley WD; Brown MP; Barritt GJ
Cancer Gene Ther; 2003 Aug; 10(8):611-25. PubMed ID: 12872143
[TBL] [Abstract][Full Text] [Related]
14. ERRgamma suppresses cell proliferation and tumor growth of androgen-sensitive and androgen-insensitive prostate cancer cells and its implication as a therapeutic target for prostate cancer.
Yu S; Wang X; Ng CF; Chen S; Chan FL
Cancer Res; 2007 May; 67(10):4904-14. PubMed ID: 17510420
[TBL] [Abstract][Full Text] [Related]
15. Targeting of prostate cancer cells by a cytotoxic lentiviral vector containing a prostate stem cell antigen (PSCA) promoter.
Petrigliano FA; Virk MS; Liu N; Sugiyama O; Yu D; Lieberman JR
Prostate; 2009 Sep; 69(13):1422-34. PubMed ID: 19489029
[TBL] [Abstract][Full Text] [Related]
16. Tumour cell radiosensitization using constitutive (CMV) and radiation inducible (WAF1) promoters to drive the iNOS gene: a novel suicide gene therapy.
Worthington J; Robson T; O'Keeffe M; Hirst DG
Gene Ther; 2002 Feb; 9(4):263-9. PubMed ID: 11896465
[TBL] [Abstract][Full Text] [Related]
17. JunD mediates androgen-induced oxidative stress in androgen dependent LNCaP human prostate cancer cells.
Mehraein-Ghomi F; Lee E; Church DR; Thompson TA; Basu HS; Wilding G
Prostate; 2008 Jun; 68(9):924-34. PubMed ID: 18386285
[TBL] [Abstract][Full Text] [Related]
18. Regulation of IkappaB kinase epsilon expression by the androgen receptor and the nuclear factor-kappaB transcription factor in prostate cancer.
Péant B; Diallo JS; Lessard L; Delvoye N; Le Page C; Saad F; Mes-Masson AM
Mol Cancer Res; 2007 Jan; 5(1):87-94. PubMed ID: 17259348
[TBL] [Abstract][Full Text] [Related]
19. Transcription-targeted gene therapy for androgen-independent prostate cancer.
Martiniello-Wilks R; Tsatralis T; Russell P; Brookes DE; Zandvliet D; Lockett LJ; Both GW; Molloy PL; Russell PJ
Cancer Gene Ther; 2002 May; 9(5):443-52. PubMed ID: 11961667
[TBL] [Abstract][Full Text] [Related]
20. Protection of androgen-dependent human prostate cancer cells from oxidative stress-induced DNA damage by overexpression of clusterin and its modulation by androgen.
Miyake H; Hara I; Gleave ME; Eto H
Prostate; 2004 Dec; 61(4):318-23. PubMed ID: 15389725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
